XGal-3® Apheresis Column
Sepsis/Septic Shock
Key Facts
About Eliaz Therapeutics
Eliaz Therapeutics is a private, pre-revenue MedTech company pioneering a novel extracorporeal therapy targeting Galectin-3 (Gal-3), a protein implicated in sepsis, kidney disease, fibrosis, and cancer progression. Its lead asset, the XGal-3® apheresis column, has received FDA Breakthrough Device Designation for sepsis and is supported by NIH funding and a strategic manufacturing collaboration with Terumo BCT. The company's platform technology aims to create a new standard of care in critical care and chronic disease by physically removing a root-cause inflammatory driver, leveraging existing hospital infrastructure for potential rapid adoption.
View full company profileAbout Eliaz Therapeutics
Eliaz Therapeutics is a private, pre-revenue MedTech company pioneering a novel extracorporeal therapy targeting Galectin-3 (Gal-3), a protein implicated in sepsis, kidney disease, fibrosis, and cancer progression. Its lead asset, the XGal-3® apheresis column, has received FDA Breakthrough Device Designation for sepsis and is supported by NIH funding and a strategic manufacturing collaboration with Terumo BCT. The company's platform technology aims to create a new standard of care in critical care and chronic disease by physically removing a root-cause inflammatory driver, leveraging existing hospital infrastructure for potential rapid adoption.
View full company profileAbout Eliaz Therapeutics
Eliaz Therapeutics is a private, pre-revenue MedTech company pioneering a novel extracorporeal therapy targeting Galectin-3 (Gal-3), a protein implicated in sepsis, kidney disease, fibrosis, and cancer progression. Its lead asset, the XGal-3® apheresis column, has received FDA Breakthrough Device Designation for sepsis and is supported by NIH funding and a strategic manufacturing collaboration with Terumo BCT. The company's platform technology aims to create a new standard of care in critical care and chronic disease by physically removing a root-cause inflammatory driver, leveraging existing hospital infrastructure for potential rapid adoption.
View full company profile